Core Scientific, Inc. filings document its high-density colocation data center business, digital asset mining activities, capital structure and public-company governance. Recent 8-K reports cover operating and financial results, Regulation FD disclosures, campus expansion updates, material agreements, debt financing and direct financial obligations.
The company’s filings also describe common stock and warrant securities listed on the Nasdaq Global Select Market, subsidiary financing arrangements, senior secured notes, credit agreement amendments, executive and accounting-officer governance matters, and annual proxy disclosures for shareholder voting, board matters and compensation programs.
Valiant Capital Management filed an amendment on Schedule 13G reporting beneficial ownership of 16,213,103 shares of Core Scientific, Inc. common stock, equal to 5.1% of the class. The percentage is calculated using 317,885,292 shares outstanding as of May 1, 2026. The filing states the holding is reported jointly by Valiant Capital Management, L.P., Valiant Capital Management, LLC and Christopher R. Hansen, with shared voting and shared dispositive power over the 16,213,103 shares. The reporting persons disclaim membership in a group and disclaim beneficial ownership except to the extent of pecuniary interest. Signatures are dated May 15, 2026.
Core Scientific, Inc. - Joint Schedule 13G/A discloses passive ownership by Citadel-related entities and Kenneth Griffin. The filing reports that Citadel Securities LLC may be deemed to beneficially own 9,357,746 shares (3.0%) and that Citadel Securities Group LP, Citadel Securities GP LLC, and Kenneth Griffin may each be deemed to beneficially own 12,792,480 shares (4.1%) based on 315,596,127 Shares outstanding as of March 23, 2026. The statement describes shared voting and dispositive power and notes certain shares issuable upon conversion of warrants.
Core Scientific, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders voted on directors, executive compensation and the independent auditor. Five directors were elected, including Adam Sullivan with 217,650,785 votes for and 2,469,826 withheld, and Elizabeth Crain with 215,074,279 for and 5,046,332 withheld.
Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 138,785,477 votes for, 79,166,695 against and 2,168,439 abstentions. They also ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 262,833,296 votes for, 313,161 against and 1,752,370 abstentions.
Core Scientific, Inc. ownership disclosure: a group of affiliated broker‑dealers led by Susquehanna entities reports beneficial ownership of 14,631,891 shares, representing 4.6% of the class. The filing states 315,594,802 Shares outstanding as of March 23, 2026. The reported holdings include option and warrant positions: 12,963,500 options and various warrants and options held across the reporting entities. The filing is a joint Schedule 13G/A by G1 Execution Services, LLC; SIG Brokerage, LP; Susquehanna Investment Group; and Susquehanna Securities, LLC, and includes a joint filing agreement.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of Common Stock on May 11, 2026 in open-market transactions. The sales occurred in two blocks at weighted average prices of $22.8162 and $23.3916 per share. The filing states the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating the transactions were scheduled in advance rather than timed discretionarily. After these sales, Duchene continues to hold a substantial direct equity position in the company, so the activity represents a small portion of his overall holdings.
Core Scientific, Inc. executive Ray Jorge L., the Chief Accounting Officer, has reported his initial beneficial ownership of company equity on a Form 3. The filing shows direct ownership of 37,998 shares of Common Stock. A related footnote describes this as a restricted stock unit grant, with one-third vesting on March 5, 2027 and the remaining two-thirds vesting in eight substantially equal quarterly installments afterward, as long as he continues providing service on each vesting date.
Core Scientific, Inc. reported sharply higher Q1 2026 revenue of $115.2 million, up from $79.5 million a year earlier, driven mainly by high-density colocation services. Colocation revenue rose to $77.5 million with a 57% gross margin, reflecting rapid expansion of AI and HPC-focused data centers.
The company recorded a net loss of $347.2 million, compared with net income of $576.3 million in Q1 2025, primarily due to $266.5 million of non-cash impairment charges on mining equipment and infrastructure as it pivots away from bitcoin self-mining. Digital asset self-mining revenue fell to $30.1 million and generated a negative gross margin.
Cash, cash equivalents and restricted cash increased to $1.15 billion, largely from a new $1.0 billion term loan facility, later refinanced via a $3.30 billion 7.75% senior secured notes issuance. Total liabilities reached $4.38 billion, and stockholders’ deficit widened to $1.31 billion. Deferred revenue climbed to $654.2 million, reflecting substantial pre-funded colocation build-outs and long-term contracts.
Core Scientific, Inc. reported sharply higher Q1 2026 revenue of $115.2 million, up from $79.5 million a year earlier, driven mainly by high-density colocation services. Colocation revenue rose to $77.5 million with a 57% gross margin, reflecting rapid expansion of AI and HPC-focused data centers.
The company recorded a net loss of $347.2 million, compared with net income of $576.3 million in Q1 2025, primarily due to $266.5 million of non-cash impairment charges on mining equipment and infrastructure as it pivots away from bitcoin self-mining. Digital asset self-mining revenue fell to $30.1 million and generated a negative gross margin.
Cash, cash equivalents and restricted cash increased to $1.15 billion, largely from a new $1.0 billion term loan facility, later refinanced via a $3.30 billion 7.75% senior secured notes issuance. Total liabilities reached $4.38 billion, and stockholders’ deficit widened to $1.31 billion. Deferred revenue climbed to $654.2 million, reflecting substantial pre-funded colocation build-outs and long-term contracts.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of the company’s common stock in open-market transactions. The sales occurred on May 4, 2026, at weighted-average prices of $21.53 for 100 shares and $20.8499 for 9,900 shares.
After these transactions, Duchene directly holds 1,980,348 shares of Core Scientific common stock. The filing notes the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of the company’s common stock in open-market transactions. The sales occurred on May 4, 2026, at weighted-average prices of $21.53 for 100 shares and $20.8499 for 9,900 shares.
After these transactions, Duchene directly holds 1,980,348 shares of Core Scientific common stock. The filing notes the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Core Scientific, Inc. reported strong top-line growth but a large loss for the first quarter of 2026 as it shifts toward high-density colocation services. Total revenue reached $115.2 million, up from $79.5 million a year earlier, driven by a surge in colocation revenue to $77.5 million from $8.6 million.
Digital asset self-mining revenue fell to $30.1 million from $67.2 million as the company continues its strategic move away from proprietary mining. Gross profit improved to $30.1 million from $8.2 million, but Core Scientific posted a net loss of $347.2 million versus net income of $576.3 million in the prior-year quarter, mainly due to $266.5 million of non-cash impairment charges and a $30.8 million non-cash loss on warrants and contingent value rights.
Non‑GAAP Adjusted EBITDA turned positive at $4.4 million compared with a loss of $6.1 million. Liquidity was $1.04 billion as of March 31, 2026, including $1.01 billion of cash and cash equivalents and $37.3 million of bitcoin. The company also highlighted a recently closed $3.3 billion 7.75% senior secured notes due 2031 and a total gross power capacity pipeline of 4.5 GW supporting its colocation growth strategy.
Core Scientific, Inc. reported strong top-line growth but a large loss for the first quarter of 2026 as it shifts toward high-density colocation services. Total revenue reached $115.2 million, up from $79.5 million a year earlier, driven by a surge in colocation revenue to $77.5 million from $8.6 million.
Digital asset self-mining revenue fell to $30.1 million from $67.2 million as the company continues its strategic move away from proprietary mining. Gross profit improved to $30.1 million from $8.2 million, but Core Scientific posted a net loss of $347.2 million versus net income of $576.3 million in the prior-year quarter, mainly due to $266.5 million of non-cash impairment charges and a $30.8 million non-cash loss on warrants and contingent value rights.
Non‑GAAP Adjusted EBITDA turned positive at $4.4 million compared with a loss of $6.1 million. Liquidity was $1.04 billion as of March 31, 2026, including $1.01 billion of cash and cash equivalents and $37.3 million of bitcoin. The company also highlighted a recently closed $3.3 billion 7.75% senior secured notes due 2031 and a total gross power capacity pipeline of 4.5 GW supporting its colocation growth strategy.
Core Scientific, Inc. announced that its subsidiary Core Scientific Finance I LLC completed a private offering of $3.3 billion aggregate principal amount of 7.750% senior secured notes due 2031. The notes priced at 99.250% of principal, with interest paid semi-annually each May 15 and November 15, starting November 15, 2026.
The issuer expects net proceeds of about $3.24 billion. It will fund a debt service reserve account and distribute the remaining proceeds to Core Scientific. Core Scientific plans to use a portion of those funds to fully repay borrowings under its delayed-draw bridge credit facility of up to $1.0 billion, including accrued interest and related fees.
The notes are senior secured obligations, guaranteed by the issuer’s five datacenter subsidiaries and secured by first‑priority liens on substantially all of their assets, specified equity interests, and certain parent assets. Principal amortizes semi‑annually at an initial rate of 11.50% per annum, and the indenture includes customary redemption, repurchase, covenant and event‑of‑default provisions, plus a completion guarantee by Core Scientific for specified datacenter projects.
Core Scientific, Inc. announced that its subsidiary Core Scientific Finance I LLC completed a private offering of $3.3 billion aggregate principal amount of 7.750% senior secured notes due 2031. The notes priced at 99.250% of principal, with interest paid semi-annually each May 15 and November 15, starting November 15, 2026.
The issuer expects net proceeds of about $3.24 billion. It will fund a debt service reserve account and distribute the remaining proceeds to Core Scientific. Core Scientific plans to use a portion of those funds to fully repay borrowings under its delayed-draw bridge credit facility of up to $1.0 billion, including accrued interest and related fees.
The notes are senior secured obligations, guaranteed by the issuer’s five datacenter subsidiaries and secured by first‑priority liens on substantially all of their assets, specified equity interests, and certain parent assets. Principal amortizes semi‑annually at an initial rate of 11.50% per annum, and the indenture includes customary redemption, repurchase, covenant and event‑of‑default provisions, plus a completion guarantee by Core Scientific for specified datacenter projects.